The binding of
urinary trypsin inhibitor (UTI) to its binding sites/receptors on
tumor cells inhibits cell invasion in a number of experimental systems and that UTI downregulates constitutive and
phorbol ester-induced
urokinase production by certain
tumor cells. To determine whether the
carbohydrate moieties and core
protein are required for
urokinase suppression, we obtained UTI derivatives that contained O-
glycoside-linked N-terminal
glycopeptide (UTIm1), N-
glycoside-linked C-terminal tandem Kunitz domains (UTIm2), UTI lacking O-
glycoside (UTIc), asialo UTI (UTIa), UTI lacking N-
glycoside (UTIn), purified Kunitz domain II of UTI (HI-8), and recombinant Kunitz domain II of UTI (R-020). The IC(50) of inhibiting binding of (125)I-labeled UTI to cells was indistinguishable for UTIa, UTIn and intact UTI, whereas the IC(50) for inhibiting binding of (125)I-labeled UTI to cells was 2.5-, 25- and 29-fold greater for UTIm1, UTIm2 and UTIc than for native UTI. We next looked at the suppression of the
urokinase expression by UTI derivatives. An
enzyme-linked
immunosorbent assay was carried out to measure secreted and cell-associated
urokinase. Intact UTI, UTIa, or UTIn effectively suppressed
urokinase expression, but UTIm1, UTIm2, UTIc, HI-8 and R-020 had no significant effect. These data show that UTI requires either the N-terminal extension with the O-linked
carbohydrate moiety (
chondroitin 4-sulfate sugar side chain; Ala1 to Lys21 residues) or the Kunitz domain I (Lys22 to Arg77 residues) of UTI to bind to cells, but the
urokinase expression was inhibited only by the O-
glycoside-linked core
protein without the N-
glycoside side chain.